Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $155.
September 16, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Charles Duncan has reiterated an Overweight rating for Neurocrine Biosciences, maintaining a price target of $155. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $155 by a reputable analyst suggests a positive outlook for Neurocrine Biosciences. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100